A Prospective Randomised Clinical Trial Evaluating Pulpotomy in Primary Molars With Three Bioceramic Calcium Silicate Cements: 24 Month Follow-Up.

IF 2.3 3区医学 Q2 DENTISTRY, ORAL SURGERY & MEDICINE

International journal of paediatric dentistry Pub Date : 2024-12-06 DOI:10.1111/ipd.13288

Abhinav L Talekar, Prasad K Musale, Gayatri S Chaudhari, Tayaba M H Silotry, William F Waggoner

{"title":"A Prospective Randomised Clinical Trial Evaluating Pulpotomy in Primary Molars With Three Bioceramic Calcium Silicate Cements: 24 Month Follow-Up.","authors":"Abhinav L Talekar, Prasad K Musale, Gayatri S Chaudhari, Tayaba M H Silotry, William F Waggoner","doi":"10.1111/ipd.13288","DOIUrl":null,"url":null,"abstract":"Background: In recent times, bioceramic calcium silicates have gained attention due to high success rates with pulpotomy in primary teeth.Aims: To evaluate and compare the clinical and radiographic outcomes of three different bioceramic calcium silicate cements in vital deciduous teeth treated with pulpotomies over a period of 24 months.Design: Children aged 4-9 years, with deep dentinal caries (ICDAS 4-6) in primary molars, having no history of spontaneous pain or signs of non-vitality were included in the study. Following clinical and radiographic evaluation 117 primary molars diagnosed as having reversible pulpitis received pulpotomy treatment, after randomly being assigned into three groups based on the bioceramic calcium silicate medicament used: a pre-mixed syringe-loaded MTA putty (NeoPUTTY); a traditional powder-liquid hand mix MTA material (NeoMTA Plus), and a precapsulated, trituration mixed material (Biodentine). Clinical and radiographic evaluation was done at 6, 12, 18 and 24 months.Results: The cumulative clinical and radiographic success for NeoPUTTY was 92%, NeoMTA Plus 97% and for Biodentine 95% and 89%, respectively, after 24 months follow-up.Conclusion: The clinical and radiographic success rates of all three bioceramic calcium silicate cements were found to be high, with no significant differences over a period of 24 months.Trial registration: Clinical trial registration number: CTRI/2021/03/031655.","PeriodicalId":14268,"journal":{"name":"International journal of paediatric dentistry","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of paediatric dentistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/ipd.13288","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In recent times, bioceramic calcium silicates have gained attention due to high success rates with pulpotomy in primary teeth.

Aims: To evaluate and compare the clinical and radiographic outcomes of three different bioceramic calcium silicate cements in vital deciduous teeth treated with pulpotomies over a period of 24 months.

Design: Children aged 4-9 years, with deep dentinal caries (ICDAS 4-6) in primary molars, having no history of spontaneous pain or signs of non-vitality were included in the study. Following clinical and radiographic evaluation 117 primary molars diagnosed as having reversible pulpitis received pulpotomy treatment, after randomly being assigned into three groups based on the bioceramic calcium silicate medicament used: a pre-mixed syringe-loaded MTA putty (NeoPUTTY); a traditional powder-liquid hand mix MTA material (NeoMTA Plus), and a precapsulated, trituration mixed material (Biodentine). Clinical and radiographic evaluation was done at 6, 12, 18 and 24 months.

Results: The cumulative clinical and radiographic success for NeoPUTTY was 92%, NeoMTA Plus 97% and for Biodentine 95% and 89%, respectively, after 24 months follow-up.

Conclusion: The clinical and radiographic success rates of all three bioceramic calcium silicate cements were found to be high, with no significant differences over a period of 24 months.

Trial registration: Clinical trial registration number: CTRI/2021/03/031655.

查看原文本刊更多论文

一项前瞻性随机临床试验评估三种生物陶瓷硅酸钙胶结剂对一磨牙髓切开术的疗效：随访24个月。

背景：近年来，生物陶瓷硅酸钙因其在乳牙切髓术中的高成功率而受到人们的关注。目的：评价和比较三种不同硅酸钙生物陶瓷粘接剂在乳牙切牙术后24个月的临床和影像学结果。设计：年龄4-9岁，患有乳牙深部龋（ICDAS 4-6），无自发性疼痛史或无活力迹象的儿童纳入研究。经过临床和影像学评估，117颗被诊断为可逆性牙髓炎的初磨牙接受了截髓治疗，根据所使用的生物陶瓷硅酸钙药物随机分为三组：预混合注射器加载MTA灰泥（NeoPUTTY）；一种是传统的粉状液体混合MTA材料（NeoMTA Plus），另一种是预胶囊营养性混合材料（Biodentine）。分别于6、12、18和24个月进行临床和影像学评估。结果：经过24个月的随访，NeoPUTTY的累积临床和放射学成功率为92%，NeoMTA Plus为97%，Biodentine为95%和89%。结论：三种硅酸钙生物陶瓷骨水泥的临床和影像学成功率均较高，在24个月内无显著差异。临床试验注册号：CTRI/2021/03/031655。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International journal of paediatric dentistry 医学-小儿科

CiteScore

5.50

自引率

2.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The International Journal of Paediatric Dentistry was formed in 1991 by the merger of the Journals of the International Association of Paediatric Dentistry and the British Society of Paediatric Dentistry and is published bi-monthly. It has true international scope and aims to promote the highest standard of education, practice and research in paediatric dentistry world-wide. International Journal of Paediatric Dentistry publishes papers on all aspects of paediatric dentistry including: growth and development, behaviour management, diagnosis, prevention, restorative treatment and issue relating to medically compromised children or those with disabilities. This peer-reviewed journal features scientific articles, reviews, case reports, clinical techniques, short communications and abstracts of current paediatric dental research. Analytical studies with a scientific novelty value are preferred to descriptive studies. Case reports illustrating unusual conditions and clinically relevant observations are acceptable but must be of sufficiently high quality to be considered for publication; particularly the illustrative material must be of the highest quality.